Articles tagged with Drug Targets
A new study found that COVID-19 infection increased the risk of heart attack and stroke for up to three years after infection. The risk was higher among people with A, B or AB blood types compared to type O, according to researchers analyzing data in the UK Biobank.
Researchers argue that stigma can play a huge role in health outcomes, leading to disengagement from care, coerced sterilization, and lack of informed choices. Addressing stigma through evidence-based approaches, such as staff training and relationship building, can improve healthcare services.
Researchers created SmartCADD, an AI-powered virtual tool combining quantum mechanics and Computer Assisted Drug Design techniques. The tool speeds up the screening of chemical compounds, significantly reducing drug discovery timelines and identifying promising HIV drug candidates.
Removing protected class regulation from Medicare Part D policies could reduce US prescription drug spending, potentially saving $47 billion between 2011-2019. The study found that rebates for protected classes of drugs grew at a slower pace than non-protected classes.
Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.
Researchers have developed a promising new drug, RI-AG03, that successfully targets and blocks both major aggregation-promoting 'hotspots' of the Tau protein. The peptide-based approach shows significant potential in preventing the build-up of Tau proteins and neurodegeneration, addressing a critical gap in current treatments.
A study by TIFR Mumbai and collaborators has identified the ventral hippocampus as a critical brain region in mediating the anxiolytic effects of psychedelics like DOI. The researchers found that targeting parvalbumin-positive interneurons in this region is key to reducing anxiety behavior.
A team of researchers has designed a new antimalarial drug called MED6-189, which is effective against both drug-sensitive and drug-resistant strains of human malaria parasites. The compound works by targeting the apicoplast organelle and vesicular trafficking pathways, making it a promising lead in the fight against malaria.
A new study suggests the hormone hepcidin may trigger psoriasis by causing iron overload in the skin. This excess iron amplifies the damaging effects of UV sunlight, leading to hyperproliferative chronic diseases like psoriasis. A potential treatment targeting hepcidin could improve treatment options for millions.
Researchers at the University of Virginia Health System have identified a crucial biological switch that regulates renin production in certain cells, allowing them to control blood pressure. This discovery provides important direction for future research into high blood pressure and cardiovascular disease treatment.
A Phase II study led by Cedars-Sinai demonstrates that a monoclonal antibody treatment is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission. The therapy targets TL1A, a protein that contributes to the severity of the disease.
A new study found that a high body roundness index over 6 years was associated with an increased risk of developing cardiovascular disease in adults older than 45. The study, published in the Journal of the American Heart Association, suggested that BRI may be a valuable predictor of cardiovascular disease risk.
A study published in Neuron found that psychedelics, such as DOI, activate fast-spiking interneurons in the ventral hippocampus, which helps to silence other neighboring neurons and reduce anxiety in mice and rats. This understanding of brain chemistry could lead to the development of new drugs targeting anxiety.
The 2024 guideline provides comprehensive recommendations for assessing cardiovascular disease risk and managing patients taking SGLT2-inhibitors. It also highlights the importance of judicious screening and evidence-based management of cardiovascular conditions before, during, and after noncardiac surgery.
Jenny Hoang, a senior at the University of Texas at Arlington, received the third-place award for her research on diazo compounds. The LSAMP program has inspired her to pursue medical school and encouraged other students to aim for Ph.D.s in physics or particle physics.
The LYFE-III study will digitize the intervention and make it freely available, assessing its effectiveness. The current research builds on previous studies that focused on parenting skills enhancement and substance abuse prevention among Latino youth.
Researchers at MIT found that a two-dose schedule for an HIV vaccine can generate a strong response to the virus, outperforming a traditional seven-dose regimen. The first dose primes the immune system, helping it to produce antibodies more effectively when a larger dose is administered one week later.
Researchers isolated drug-resistant strains of SARS-CoV-2 from immunocompromised individuals who received antiviral treatments. The virus variants showed resistance to Paxlovid and remdesivir, highlighting the need for combination therapy to treat COVID-19 in highly vulnerable patients.
A new scientific statement emphasizes the role of social determinants, such as immigration status, socioeconomic position, and access to healthcare, in shaping cardiovascular health among Asian American adults. The statement identifies future research directions to advance health equity and reduce disparities in these communities.
A systematic review of pharmacogenomics clinical decision support systems found that e-health tools can help integrate personalized medicine into everyday clinical practice. However, current implementation is limited, particularly in non-US healthcare systems.
Researchers at NYU Abu Dhabi have developed nanoscale covalent organic frameworks (nCOFs) modified with peptides to treat triple-negative breast cancer. The COFs selectively release drug cargo within the acidic environment of tumors, improving treatment effectiveness and minimizing side effects.
Researchers aim to find a new treatment pathway for diabetic retinopathy by targeting the IL-6 protein. They suspect that selectively inhibiting trans-signaling while allowing cis-signaling will stop damage and restore balance in the retina.
A team at Medical University of South Carolina identified a pathway to reduce fat accumulation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). They used a novel stem cell platform and screened 1,100 compounds to find five that more than halved fat droplets on treated liver cells.
The FDA Letter of Support recognizes the potential of αSyn-SAA to accelerate clinical trial design in Parkinson's and related disorders. This biomarker can objectively detect early biology related to these diseases, enabling research toward tailored therapies and potentially delaying or preventing disease onset.
Researchers at UCSF identified signals in the metabolic system of infants who died from Sudden Infant Death Syndrome (SIDS), finding associations between lower C-3 levels and elevated C-14OH. Elevated biomarkers also led to reduced risk of SIDS, but further research is needed to validate these findings.
Researchers at Nagoya University have developed a method to chemically alter siRNAs, reducing off-target effects and improving the safety of siRNA drugs for genetic therapy. By modifying the seed region of siRNAs with formamide, they achieved suppression of off-target effects with higher efficiency than existing chemical modifications.
A new study published in Cell Systems uses artificial intelligence to map regulatory networks in patient tumors and identifies four drug candidates for neuroendocrine, liver, and renal cancers. The researchers validated these candidates in cells, showing that inhibiting them significantly affected cancer cell growth.
Researchers investigated peptide clumping behavior using molecular dynamics simulations and AI techniques. They discovered that aromatic amino acids enhance aggregation, while hydrophilic ones inhibit it, offering insights into peptide structure and function.
A clinical trial led by UC San Francisco aims to develop new therapies for progressive supranuclear palsy, with a focus on reducing time to find effective treatments and increasing diverse participant enrollment. The five-year grant could lead to the first effective drugs for this incurable neurodegenerative disorder.
A randomized controlled trial found that transcatheter edge-to-edge repair (M-TEER) significantly reduced cardiovascular death and hospitalizations for heart failure, compared to medical therapy alone. The study also showed improved health status in patients with moderate to severe functional mitral regurgitation.
A phase 3 study has shown that vutrisiran, an RNA interference therapeutic, reduces all-cause mortality and recurrent cardiovascular events by 28% and 33% respectively in patients with transthyretin amyloidosis with cardiomyopathy. The treatment also improves functional capacity, quality of life, and NYHA class.
Researchers discovered that the blood coagulation protein fibrin causes unusual clotting and inflammation in COVID-19, suppressing the body's ability to clear the virus. A promising therapeutic strategy has been identified, targeting fibrin to combat these deleterious effects.
The LENN system protects and efficiently releases NA therapies within the cytoplasm of target cells, overcoming low efficiencies and immune system clearance issues. It is biomanufacturable, biodegradable, and highly tunable, targeting a variety of cells depending on their tumor-specific surface markers.
A new study published in the Stroke journal found that people with brain aneurysms are at higher risk of developing mental health conditions, including anxiety. The study, which analyzed data from over 85,000 people, found that younger adults were particularly vulnerable to this increased risk.
A newly developed compound, MOD06051, targets neutrophils and reduces harmful inflammation in rat models. This approach differs from current treatments that may have broader immunosuppressive effects, offering a safer alternative.
Researchers developed tumor cell-coated carbon nanohorns to deliver paclitaxel to colon cancer, exhibiting high accumulation at tumors and strong chemotherapeutic effects. The treatment also demonstrated a robust photothermal effect and immune responses, effectively destroying tumors.
A recent study found that Chinese patients with ovarian cancer often carry a specific variant of the RAD51D gene, which can promote tumor growth. The variant also makes these patients more sensitive to PARP inhibitors, leading to a favorable prognosis and potential new treatment methods.
Researchers have discovered a new site on beta-2 adrenergic receptors that allows healthy signals to pass through, minimizing harmful side effects of beta-blocker medication. The gut microbial pathway is associated with cardiovascular disease risks and can be independently targeted.
Researchers have identified lower levels of certain amino acids in the blood plasma of patients with unexplainable chronic itch, offering a potential breakthrough in treating this debilitating condition. These findings may pave the way for new targeted therapies.
A new treatment targeting two tumor-feeding genes is being tested to treat non-small cell lung cancer. The therapy, called PEPD-G278D, breaks down genetic mutations that contribute to drug resistance, showing strong suppression of NSCLC cell function and tumors.
A new study found that mTORC1 activity correlates with classical biometrics, such as height and macrocephaly, as well as specific neuropsychiatric diseases like anxiety and autism. The research suggests that human variability of mTORC1 gain of function may predict medication response.
A new editorial published in Aging suggests that starting targeted cancer therapies with high concentrations may slow down the selection for resistance. This approach could potentially be used as a preemptive measure to minimize the development of resistance.
A recent study published in CANCER found that patients with metastatic non–small cell lung cancer treated with immunotherapy had improved overall and cancer-specific survival rates compared to those without it. The median overall survival was eight months, while cancer-specific survival was 10 months.
A new study has shown that a drug developed for pancreatic cancer is effective in treating the most aggressive form of medulloblastoma, a childhood brain tumor. The drug, Minnelide, reduced tumor growth and increased the efficacy of chemotherapy, offering hope for improved survival rates for children with this disease.
A study of non-statin cholesterol-lowering medications found that cholesterol absorption inhibitors were associated with a 31% lower odds of liver cancer risk. Statin use was also linked with a 35% lower risk. Fibrates, omega-3 fatty acids, and niacin showed no association.
A team of researchers has developed a comprehensive ranking of genes and proteins involved in Alzheimer's disease, providing a roadmap for more targeted research and drug discovery. The study integrates findings from multiple fields and identifies thousands of potential therapeutic targets.
Researchers developed a triple-adeno-associated virus vector system to deliver full-length dystrophin protein into muscles, restoring muscle health and strength in mice models with Duchenne muscular dystrophy. The approach has shown promise for treating patients with the genetic disorder.
A blood test measures lymphocyte count to predict treatment response in relapsed multiple myeloma. Patients with higher lymphocyte counts experience better cancer control for longer periods.
Researchers at the Mayo Clinic Comprehensive Cancer Center discovered a new treatment approach that improved survival rates for patients with B-cell precursor leukemia by nearly 60%. The study found that adding blinatumomab to chemotherapy reduced the risk of leukemia recurrence and death.
A recent study at the University of Missouri discovered that oxytocin and corticotropin-releasing hormone cause the brainstem to become overactive, leading to hypertension. This finding can help develop targeted drugs to reduce high blood pressure in sleep apnea patients.
Scientists at Trinity College Dublin have identified a key biological pathway, the JAK/STAT pathway, that RSV suppresses and prevents immune system igniters from activating. This discovery provides a promising new target for therapeutic immune restoration and could lead to significant impact in treating RSV infections.
Mayo Clinic scientists have established criteria for a memory-loss syndrome in older adults that specifically impacts the brain's limbic system. The syndrome, called Limbic-predominant Amnestic Neurodegenerative Syndrome (LANS), progresses more slowly and has a better prognosis than Alzheimer's disease.
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
Researchers created a new cell model to study the effects of senescence on lung fibroblasts. Senescent alveolar epithelial cells triggered fibrotic activation in lung fibroblasts, which was attenuated by senolytic therapy.
Researchers identified a viable path to developing a novel therapy that would make opioids more effective and safer as a treatment for chronic pain. The study found that selective Hsp90 inhibitors amplified the pain-relieving effects of morphine, reducing tolerance and side effects.
Researchers discuss the use of antibody-drug conjugates (ADCs) in treating biologically aggressive tumors, such as uterine serous carcinoma. The ADC T-DXd has shown remarkable preclinical activity against primary USC cells lines and xenografts overexpressing HER2/neu.
A large nationally representative study found that only 2.9% of U.S. adults had ever used nicotine pouches, with a lower percentage reporting current use. The study suggests that the majority of adult pouch consumers are using them to 'top off' nicotine in situations where they cannot smoke or use other tobacco products.
A new study by the University of Toronto Nursing found that over one million industry-sponsored events took place in the US in 2022, with a focus on physician and nurse practitioner interactions. These events were linked to specific pharmaceutical products, indicating their potential impact on prescribing practices.
Researchers discovered Pradimicin A's molecular basis for binding to viral N-glycan, showing promise as an anti-SARS-CoV-2 drug. The compound inhibits SARS-CoV-2 infectivity by interacting with branched oligomannose-containing glycans.
A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.